DES vs BMS in diabetics n nondiabetics

0 views

Skip to first unread message

Murali R

unread,

Oct 10, 2008, 2:02:17 AM10/10/08

to Invasive CVTS Group

DES vs BMS in diabetics n nondiabetics:

Conclusion:

In trials with a duration of dual antiplatelet therapy of
six months or longer drug eluting stents were safe and
effective in people with and without diabetes. It seems
prudent to adhere to a minimal duration of dual
antiplatelet therapy of six months in patients undergoing
implantation of a drug eluting coronary stent.
The potential benefits of a longer duration of therapy
need to be balanced against potential risks, such as
clinically relevant bleeding. The optimal duration can
only be determined in adequately powered large scale
randomised controlled trials.